v3.25.2
Operating Segments (Tables)
 12 Months Ended
Dec. 31, 2024
Operating Segments [Abstract]  
Schedule of Operating Segments

The Group’s CODM is the CEO of the Company.

 

   Year ended December 31, 2024 
   Drug
Development		   Online
Sales		   Total 
Revenues            
External  $
-
   $1,306   $1,306 
Total   
-
    1,306    1,306 
                
Segment loss (gain)   4,873    2,443    7,316 
                
Equity losses from the investment in MitoCareX             429 
Finance expense (income), net             (259)
Tax income             (14)
                
 Loss             7,472 

 

   Year ended December 31, 2023 
   Drug
Development		   Online
Sales		   Total 
Revenues            
External  $
-
   $2,879   $2,879 
Total   
-
    2,879    2,879 
                
Segment loss (gain)   5,359    1,456    6,815 
                
Company’s share of losses of company accounted for at equity, net             210 
Finance expense (income), net             (1,164)
Tax expense             22 
                
Loss             5,883 
   Year ended December 31, 2022 
   Drug
Development		   Online
Sales		   Total 
Revenues            
External  $-   $1,347   $1,347 
Total   -    1,347    1,347 
                
Segment loss   8,405    (118)   8,287 
Company’s share of losses of company accounted for at equity, net             109 
Finance expense (income), net             (5,818)
Tax expense             14 
                
 Loss             2,592 

 

 

   As of December 31, 2024 
   Drug
Development		   Online
Sales		   Total 
             
Segment Assets  $8,407   $1,764   $10,171 
Segment Liabilities  $1,194   $226   $1,420 

 

   As of December 31, 2023 
   Drug
Development		   Online
Sales		   Total 
             
Segment Assets  $7,069   $4,113   $11,182 
Segment Liabilities  $1,441   $154   $1,595